Project Grant R41CA285188
Award Date
8/1/24
Completion Date
7/31/25
Dollars Obligated
$800K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program "Cancer Treatment Research" (CFDA 93.395), provides $400,000 to Cancer Targeted Technology LLC to develop and validate an innovative PSMA-targeted small molecule prodrug (CTT2274) for the treatment of advanced prostate cancer. The key products and services to be delivered include:
Performing process development and optimization on the CTT2274 synthetic procedures.
Assessing the...
This $545,078 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a combination therapy to enhance the efficacy of radiopharmaceutical therapy for prostate cancer (PC) and renal cell carcinoma (RCC).
The research will systematically evaluate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical therapy (PSMA-RPT) on glutaminolysis, a critical metabolic pathway in these cancers. The project will...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $393,401 to Washington State University to develop a novel PSMA-targeted small-molecule dual drug conjugate (SMDDC) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and other PSMA-positive malignancies. The overall objective is to create an SMDDC that can selectively deliver a synergistic combination of two distinct chemotherapeutic payloads to...
The National Cancer Institute (NCI) awarded a $692,072 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The University of Texas Southwestern Medical Center. The grant, effective September 19, 2024 through August 31, 2029, aims to develop a multimodal theranostic platform targeting prostate cancer (PC).
The proposed theranostic agents leverage Prostate-Specific Membrane Antigen (PSMA) targeting to enable concurrent positron emission tomography/computed...
The National Cancer Institute awarded a $422,874 Project Grant (R21CA282396) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of Connecticut Health Center (UCHC) to develop a well-defined in vitro model that mimics the bone-tumor microenvironment of metastatic prostate cancer. The goal is to create a flexible 3D bioprinted tumor model that can serve as a preclinical screening platform to enhance the development of novel therapeutic agents.
As part of...
This $586,967.00 Project Grant award under the National Institute of Biomedical Imaging and Bioengineering's Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286) program aims to develop a novel theranostic agent, PSMA-1-PC413, for fluorescence-guided surgery and photodynamic therapy to treat prostate cancer. The research will be conducted by Case Western Reserve University, focusing on using the prostate-specific membrane antigen (PSMA) biomarker...
The National Cancer Institute (NCI) awarded a $898,497 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to Radiopharmaceutical Imaging And Dosimetry, LLC to develop a cloud-based, customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies (ARPT).
The key products and services to be delivered under this Phase II Small Business Innovation Research (SBIR) grant include:
Establishing a library of microscale S-values and apportionment factors...
This Federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $400,000 to Nuago Therapeutics Inc. to develop an RNA interference-based therapeutic for prostate cancer. The funding will support preclinical research and development of the "NU002" therapy, which consists of short interfering RNA molecules targeting genes essential for cancer cell survival. The research aims to evaluate the uptake and...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research focused on overcoming mechanisms of PTPN1 driving therapy- and castration-resistant prostate cancer with novel theranostics. The $472,458 grant, awarded to the University of Texas Southwestern Medical Center in Dallas, TX, aims to examine the regulation of the PTPN1 gene and its role in the transdifferentiation of prostate cancer cells,...
This $696,447 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports the development and evaluation of 203Pb-labeled and 212Pb-labeled antibodies targeting the CD46 tumor epitope for SPECT imaging and targeted alpha particle therapy of malignant mesothelioma. The project aims to address the significant unmet clinical need for improved treatments, especially for the difficult-to-treat sarcomatoid and biphasic...